SCHEMBL3009901

SCHEMBL3009901

Cc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3cc(C(F)(F)F)ccc3Cl)CC2)n1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
ATM Q13315 1/20 0.40
AR P10275 3/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
MCL1 Q07820 1/20 0.37
MPL P40238 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003910 0.93 RAF1 (0.42) RAF1BRAFL3MBTL1RAB9ASMN1; SMN2
SCHEMBL3006949 0.91 AR (0.50) RAF1BRAFL3MBTL1RAB9ASMN1; SMN2
SCHEMBL3012970 0.90 AR (0.42) RAF1BRAFL3MBTL1RAB9ASMN1; SMN2
SCHEMBL3011421 0.89 AR (0.44) L3MBTL1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL3020324 0.89 RAB9A (0.51) RAF1BRAFL3MBTL1RAB9ASMN1; SMN2
SCHEMBL3014627 0.88 AR (0.44) L3MBTL1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL3009425 0.88 MEN1 (0.49) L3MBTL1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL3011986 0.86 SMN1; SMN2 (0.47) L3MBTL1RAB9ASMN1; SMN2NPC1MEN1
SCHEMBL3009295 0.86 AR (0.43) RAF1BRAFL3MBTL1RAB9ASMN1; SMN2
SCHEMBL3008837 0.86 SMN1; SMN2 (0.49) L3MBTL1RAB9ASMN1; SMN2NPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAF1 3057/4885BRAF 2732/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.